Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone

MT Newswires Live

02/27

Vanda Pharmaceuticals (VNDA) has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.

The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2614378855"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614378855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614378855?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614378855","market":"nz","top_or_hot":-1,"title":"Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone","media":"MT Newswires Live","content":"<html><body><p> Vanda Pharmaceuticals (VNDA) has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.</p><p>The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vanda Pharmaceuticals (VNDA) has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.</p><p>The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHMP","symbol_name":"冠军工业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614378855","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614378855","pubTimestamp":1772196745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vanda Pharmaceuticals  has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHMP":"冠军工业","MDCO":"麦迪逊医药","BK4087":"商业印刷","BK4139":"生物科技","VNDA":"万达生物制药"},"translate_title":"Vanda Pharmaceuticals收到欧洲药品管理局CHMP对伊潘立酮的负面意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNDA":1.5,"MDCO":1.5,"CHMP":1.5},"content_text":"Vanda Pharmaceuticals (VNDA) has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}